Meletios Dimopoulos; ASH 2025: B-Cell Maturation Antigen Bispecific Antibody Linvoseltamab Brings High Response Rates in Patients with Relapsed/Refractory Multiple Myeloma

episode

Audio Journal of Oncology Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

NPR News: 09-24-2026 2AM EDT 5 min · 24 Sep 2026 · NPR News Now

Entertainment Catch-Up: Presley Gerber, Phones in Theatres and Channing Tatum's Troll Account(?) 39 min · 24 Sep 2026 · Catch Up with Louise McSharry

2AM ET 09/24/2026 Newscast 3 min · 24 Sep 2026 · Fox News Hourly Update

How To Naturally Lift & Sculpt Your Face, Define Your Jawline & Age Better Without Injectables 1h 3m · 24 Sep 2026 · The Bossticks

Cómo dejar ir a alguien que todavía amas | Jueves de Lety & Ash | Episodio 697 22 min · 24 Sep 2026 · Se Regalan Dudas

Dead Internet 2026: DARPA, Peter Thiel, Alien AI & Memetic Magick 1h 47m · 24 Sep 2026 · Occult Symbolism and Pop Culture with Isaac Weishaupt

Report any issue

Source

Recorded20 Jan 2026

Publisheraudiomedica.com ↗

Handlerec:19315689

Show notes

Meletios Dimopoulos MD, Chair of Clinical Therapeutics at the University of Athens, discusses early findings from the phase 1b LINKER-MM2 trial presented at ASH 2025. The study reveals high clinical response rates for the B-Cell Maturation Antigen bispecific antibody linvoseltamab when combined with anti-CD38 therapy in patients with relapsed/refractory multiple myeloma. These preliminary safety and efficacy data support further development of this promising combination for MM treatment.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in